glp 1 drugs pcos Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives Liraglutide and polycystic ovary syndrome:

GLP-1 is the same hormone targeted by popular weight-loss medications like Ozempic and Wegovy

Factors such as increasing manufacturing capacities and capabilities are enhancing supply capacity to meet surging global demand for these therapies

Research has associated GLP-1 medications with a higher risk of bowel obstruction compared to other weight loss drugs

Moving from peptide-based biologics to small molecules like orforglipron redefines scalability, simplifies supply chains, and expands global reach

J Am Acad Dermatol 80(4):10291072 Ethics declarations Ethics approval Ethics approval was not required for this study

GLP-1 receptor (GLP-1R) is widely distributed in the central nervous system, mainly in neurons (Vrang and Larsen, 2010), with high expression in glutamatergic neurons of the area postrema (AP) and nucleus of the solitary tract (NTS) (McClean et al., 2011